Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use

Details for Australian Patent Application No. 2001245466 (hide)

International Classifications

Event Publications

12 May 2005 Application Accepted

Published as AU-B-2001245466

8 September 2005 Standard Patent Sealed

14 July 2011 Extension of Term of Standard Patents

Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 18 Mar 2011 For the goods ONGLYZA saxagliptin

21 July 2011 Extension of Term of Standard Patents

Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 18 Mar 2011 For the goods ONGLYZA saxagliptin Address for service in Australia: Phillips Ormonde Fitzpatrick 367 Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Applications Accepted Collins Street Melbourne VIC 3000

19 January 2012 Extension granted

Bristol-Myers Squibb Company Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Extensions granted The earliest first regulatory approval date provided by the patentee 18 Mar 2011 For the goods ONGLYZA saxagliptin Extension of Term of patent pursuant to Section 77 expires on 05 Mar 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.